bis-[(p-methoxybenzyl)cyclopentadienyl]vanadium(IV) diselenocyanate | 1227698-40-9

• 英文名称: bis-[(p-methoxybenzyl)cyclopentadienyl]vanadium(IV) diselenocyanate
• 英文别名: [η5-C5H4CH2C6H4OCH3]2V(SeCN)2
• CAS: 1227698-40-9
• 化学式: C₂₈H₂₆N₂O₂Se₂V
• 分子量: 631.388
• InChiKey: XTKIUDSEQXBMDK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  None
• 重原子数：
  None
• 可旋转键数：
  None
• 环数：
  None
• sp3杂化的碳原子比例：
  None
• 拓扑面积：
  None
• 氢给体数：
  None
• 氢受体数：
  None

反应信息

• 作为产物：
  描述：

  bis-[(p-methoxybenzyl)cyclopentadienyl]vanadium(IV) dichloride 、 potassium selenocyanate 以 四氢呋喃 为溶剂， 以80.9%的产率得到bis-[(p-methoxybenzyl)cyclopentadienyl]vanadium(IV) diselenocyanate
  参考文献：
  名称：

  Antitumor activity of vanadocene Y and its selenocyanate derivative in xenografted caki-1 tumors in mice

  摘要：

  The para-methoxybenzyl-substituted vanadocene dichloride (Vanadocene Y) (1) and its diselenocyanate (Selenocyanato-Vanadocene Y) (2) were tested in vitro in an anti-angiogenesis assay against human umbilical vein endothelial cells (HUVEC) delivering IC50 values of 0.92 +/- 0.03 mu M (1) and 37 +/- 11 mu M (2). In a cytotoxicity assay against the human renal cancer cells, CAKI-1, the compounds demonstrated IC50 values of 0.55 +/- 0.09 mu M (1) and 0.25 +/- 0.03 mu M (2). Then both compounds were given at their maximum tolerable dose, MTD, of 20 mg/kg/d (1) or 40 mg/kg/d (2) on four consecutive days or at 50% of the MTD on five consecutive days per week for three weeks to overall four cohorts of eight CAKI-1 tumor-bearing female NMRI:nu/nu mice each, while a further cohort was treated with solvent only. Both MTD-treated mouse cohorts showed a statistically significant tumor growth reduction with respect to the solvent-treated control group with an optimal T/C value of 47% on day 39 of the experiment. Immunohistological analysis revealed that the expression of the proliferation marker Ki-67 was reduced due to long-term treatment with 2. (C) 2010 Elsevier B.V. All rights reserved.

  DOI：

  10.1016/j.jorganchem.2010.01.026